ZLZhaoting Li

Zhaoting Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zhaoting Li has a total of 85 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A dual-gated engineered bacterial platform for spatiotemporally controlled precise protein degradation

    by Shangwu Sun, Ruoxi Hu, Xue Zhai, Rui Bai, Jiaming Guo, Tuoyu Zhou, Tongfu Yang, Qinglan Zeng, Yilin Zhang, Jie Yu, et al.

  • Open Access

    A tris(phthalocyanine)-appended ruthenium(II) complex induces immunogenic pyroptosis and systemic antitumor immunity

    by Jiaxin Shen, Tongfu Yang, Jie Yu, Zihang Ma, Jieyao Chen, Linpeng Zhu, Evelyn Y. Xue, Herbert Ho-Fung Loong, Peter Chi Keung Cheung, Zhaoting Li, et al.

    Photodynamic therapy (PDT) is a promising modality for cancer treatment, yet its therapeutic efficacy can be limited by aggregation-induced deactivation of photosensitizers, inefficient intracellular delivery, and insufficient activation of antitumor immunity. Herein, we report a structurally defined tris(phthalocyanine)-appended ruthenium(II) complex (Pc–Ru), in which three zinc(II) phthalocyanine (ZnPc) photosensitizing units are integrated with an intrinsically cytotoxic Ru(II) center through pyridyl–triazole coordination. This molecular architecture enhances cellular uptake and integrates photodynamic and chemotherapeutic functions within a single molecular entity, enabling synergistic chemo-photodynamic activity without reliance on an additional nanocarrier or co-loaded chemotherapeutic agent. Upon light irradiation, Pc–Ru induces pronounced mitochondrial dysfunction and activates the caspase-3/gasdermin E (GSDME) pathway, resulting in immunogenic pyroptotic cell death accompanied by the release of damage-associated molecular patterns and other immunogenic signals that promote dendritic-cell maturation. In tumor-bearing mice, Pc–Ru-mediated phototherapy markedly suppresses primary tumor growth with negligible systemic toxicity and substantially enhances intratumoral infiltration of CD4+ and CD8+ T lymphocytes. Furthermore, localized treatment in a bilateral tumor model significantly inhibits the growth of distant untreated tumors, demonstrating the generation of systemic antitumor immunity. These findings demonstrate that molecular integration of multiple photosensitizing macrocycles with a therapeutically active metal center provides a structurally defined strategy to couple chemo-photodynamic activity with caspase-3/GSDME-mediated pyroptosis and immune amplification, thereby extending localized phototherapy into systemic antitumor treatment.

  • Engineered mesenchymal stem cells regulate integrated stress response for fibrosis therapy

    by Jie Yu, Shuhua Yin, Jiong Li, Yilin Zhang, Xiuli Zhong, Nuo Zhou, Wei Li, Yixin Wang, Renke Li, Minjie Sun, et al.

  • Open Access

    Engineered Stem Cells Restore Joint Homeostasis by Amplifying Macrophage-Cartilage Dialogue in Osteoarthritis

    by Jiong Li, Cuixi Wu, Zhaoting Li, See Pdf

    Macrophages are the most abundant immune cell population in osteoarthritis (OA) joints and display aberrant activation closely associated with disease pathology. However, current macrophage-targeting strategies for OA are primarily directed toward phenotype modulation, often neglecting the crucial subsequent dialogue with articular cartilage that is essential for restoring joint homeostasis. To address this, we engineered adipose-derived mesenchymal stem cells (ASCs) with a dual-component system: i) ROS-responsive nanoparticles (RM) for reprogramming macrophages toward an anti-inflammatory phenotype, and ii) a bispecific peptide (BP) to physically bridge these macrophages with chondrocytes, thereby amplifying their therapeutic crosstalk. These fully equipped RM/BP-ASCs achieved coordinated regulation of macrophage polarization and spatial localization, effectively amplifying macrophage-cartilage communication. In both murine (DMM) and rabbit (MIA) OA models, RM/BP-ASCs demonstrated superior efficacy in alleviating pain, reducing inflammation, and promoting cartilage repair compared to control or RM-only ASCs. Mechanistically, by facilitating direct contact, the engineered stem cells unlocked the full reparative potential of anti-inflammatory macrophages. This enhanced dialogue promoted collagen turnover, increased pro-chondrogenic cytokine secretion, and restored the TGF-β/Smad2/3 signaling axis in chondrocytes, culminating in synergistic therapeutic outcomes. Overall, this study introduces a potent approach to directly mediate anti-inflammatory macrophage-cartilage interactions, offering insights into macrophage modulation for OA therapy.

  • Targeting metabolic vulnerabilities with advanced delivery systems

    by Wanlin Ye, Xin Li, Jocelyn Chandra, Jie Yu, Tuoyu Zhou, Zhaoting Li


  • Open Access

    Harnessing extracellular vesicles for ischemic stroke management

    by Khan Haroon, Jie Yu, Renke Li, Chuancheng Ren, Zhaoting Li

    Extracellular vesicles (EVs) are versatile, cell-derived complexes that serve as a complete package of biologically important molecules, released during both normal and pathological processes. With rapid advancements in EVs research, there has been a shift in its therapeutic applications, clinical development and commercialization. EVs have been extensively studied for their potential to mitigate ischemic stroke pathological mechanisms, such as excitotoxicity, immune response, blood–brain barrier (BBB) dysfunction, neuroinflammation and apoptosis. EVs’ innate ability to protect molecular cargo (proteins, DNA or RNA) from enzymatic degradation, their natural ability to traverse BBB, high cargo-loading efficiency and superior biocompatibility make them ideal candidates for targeted drug delivery systems in ischemic stroke. Their presence in most biofluids and changes in their contents during disease conditions, support investigation of EVs as promising minimally invasive biomarkers for the early diagnosis and treatment monitoring of ischemic stroke. Moreover, EVs in combination with other therapeutic agents have considerable potential for clinical translation. This perspective provides a comprehensive overview of current literature on EV-based systems in stroke management, highlighting their role as standalone therapeutics, presenting opportunities for cargo delivery, biomarkers discovery and synergistic component of combination therapies. Additionally, the ongoing clinical trials are discussed along with the challenges and considerations required to advance the clinical translation and adaptation of EV-based systems for ischemic stroke management.


  • Engineered cells for cardiovascular diseases

    by Nuo Zhou, Jocelyn Chandra, Hanxiang Zhu, Jie Yu, Wanlin Ye, Renke Li, Zhaoting Li

  • Engineering pyroptotic vesicles as personalized cancer vaccines

    by Zhaoting Li, Yixin Wang, Fanyi Mo, Tyler Wolter, Rachel Hong, Allie Barrett, Nathaniel Richmond, Fengyuan Liu, Yu Chen, Xicheng Yang, et al.

    Tumour vaccines are designed to stimulate the host’s immune system against existing tumours or tumour recurrence. However, individual differences, tumour heterogeneity and side effects hinder the applications of current tumour vaccines and require the development of personalized cancer vaccines. To overcome these challenges, we engineered pyroptotic vesicles—extracellular vesicles formed during tumour cell pyroptosis—as a tumour vaccine platform. The extracted pyroptotic vesicles possess abundant tumour antigens and potent immune-stimulating ability and, loaded into a biocompatible hydrogel, they can be implanted into post-surgical tumour cavities to prevent tumour recurrence. The pyroptotic-vesicle-based vaccine outperforms both exosome- and apoptotic-body-based vaccines in inhibiting tumour recurrence and metastasis in different post-surgical mouse models. Mechanistic studies reveal that the pyroptotic-vesicle-based vaccine could stimulate robust antigen-specific dendritic cell and T cell immune responses against both artificial OVA antigens and cancer neoantigens. In sum, our vaccine platform can be tailored to stimulate robust antitumour immune responses for treating individual cancer patients.


  • Open Access

    Engineered bacteria and bacterial derivatives as advanced therapeutics for inflammatory bowel disease

    by Jingyuan Wu, Wanlin Ye, Jie Yu, Tuoyu Zhou, Nuo Zhou, Dennis K.P. Ng, Zhaoting Li

    Inflammatory bowel disease (IBD), a chronic and relapsing-remitting condition, is inadequately managed by conventional therapies that often lack targeting specificity and carry significant side effects, particularly failing to address intestinal barrier repair and microbial balance. Probiotics, with their strong colonization capabilities, present a novel approach to drug delivery. Various engineering strategies have been developed to enhance the targeting ability of probiotics to inflammation sites, enabling precise delivery or in situ synthesis of therapeutic molecules to expand their multifunctional potential. This review discusses the recent advancements in bacterial modifications, including surface physico-chemical and biological coating, genetic engineering, outer membrane vesicles, minicells, and bacterial ghosts, all of which can enhance therapeutic localization. We also outline critical preclinical considerations, such as delivery frequency, systemic distribution, immune evasion, and gene contamination risks, for clinical translation. These engineered bacteria and bacterial derivatives hold great promise for personalized and sustained IBD treatments, providing a new frontier for therapy tailored to the complex inflammatory environment of IBD.